Yu Fan
Wedbush Securities Inc., Research Division
Okay. Good morning, everybody. Thank you for joining us today. This is Wednesday, October 8. This is the first of what we hope to be many installments in the Wedbush Rewind series in which we review key highlights from conferences in our sector. The first installment will focus on the UEGW conference in Berlin. This was a very exciting conference with many updates in the IBD space.
Joining me today is David Nierengarten, Managing Director of the Healthcare Equity Research team at Wedbush, along with Dr. Marla Dubinsky, Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai. We are also joined by David De Vries M. Phil, CEO of Tr1X Bio; as well as Taylor Schreiber, MD, PhD and CEO of Shattuck Labs.
For the audience, we encourage you to participate in our discussion with Q&A. There is a chat feature in the bottom of your window. Please ask questions to us and we will try to address them during the session and also a Q&A session at the end.
With that, I’ll turn it over to our — I will begin speaking with Dr. Marla Dubinsky, of Mount Sinai. Marla, thank you so much for joining us today. We really appreciate it.
